Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Open-Label Extension Protocol to SNK01-AD01 Study — Stella

Home/Alzheimer Disease/Open-Label Extension Protocol to SNK01-AD01 Study

View on ClinicalTrials.gov

Recruiting

Back to Alzheimer Disease trials

Open-Label Extension Protocol to SNK01-AD01 Study

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Behavioral Research Specialists, LLC, Glendale, California

Key details

Phase

Safety & dosing

Sponsor

NKGen Biotech, Inc.

Enrollment target

~30 participants

Started

June 2025

Primary completion

April 2028

Age range

40 Years – 85 Years

Last updated November 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.